{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:37:52Z","timestamp":1793759872647,"version":"4.6.1"},"reference-count":65,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2026,5,25]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    Triple-negative breast cancer (TNBC) is defined in routine practice by the absence of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) expression using fixed immunohistochemical and\n                    <jats:italic>in situ<\/jats:italic>\n                    hybridisation cut-offs. Although this framework ensures reproducibility and regulatory consistency, it does not equate to biological uniformity. TNBC is an operational clinicopathological category defined by reproducible biomarker thresholds applied to continuous gradients of receptor expression. This review examines the evolution of hormone receptor assessment from semiquantitative composite scoring systems to the current \u22651%\u2009ER positivity threshold, and analyses the diagnostic and clinical implications of ER-low-positive (1%\u201310%) tumours. We discuss the rarity and interpretative challenges of ER\u2212\/PR+ phenotypes, the impact of evolving HER2 testing criteria, including borderline amplification and HER2-low categories, and the consequences of guideline variation on TNBC classification. We also address histological heterogeneity within TNBC and propose a pragmatic three-tier framework that distinguishes definite TNBC, context-dependent\/borderline TNBC and non-TNBC categories. Collectively, these considerations highlight that TNBC is a regulatory definition anchored to diagnostic thresholds rather than a discrete molecular entity. Awareness of definitional sensitivity at receptor cut-off margins is essential for accurate reporting, avoidance of misclassification and informed multidisciplinary decision-making. Recognition of TNBC as a biologically heterogeneous spectrum has implications for therapeutic selection, trial eligibility and future refinement of classification systems.\n                  <\/jats:p>","DOI":"10.1136\/jcp-2026-210723","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T17:20:30Z","timestamp":1781025630000},"page":"505-512","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Triple-negative breast cancer: a threshold-defined diagnostic category within a biological continuum"],"prefix":"10.1136","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5009-5525","authenticated-orcid":false,"given":"Emad A","family":"Rakha","sequence":"first","affiliation":[{"name":"School of Medicine, University of Nottingham - University Park Campus, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"2026071702101074000_79.8.505.1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22381"},{"key":"2026071702101074000_79.8.505.2","unstructured":"The WHO classification of tumours editorial board: breast tumours. 5th edn. Lyon: IARC press, 2019."},{"key":"2026071702101074000_79.8.505.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.6529"},{"key":"2026071702101074000_79.8.505.4","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0904-SA"},{"key":"2026071702101074000_79.8.505.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8738"},{"key":"2026071702101074000_79.8.505.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2775"},{"key":"2026071702101074000_79.8.505.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02864"},{"key":"2026071702101074000_79.8.505.8","unstructured":"Gradishar WJ , Moran MS , Abraham J , et al . NCCN Clinical Practice Guidelines in Oncology. Breast Cancer v1.2026 (Downloaded from NCCN.org on 08 Feb 2026)."},{"key":"2026071702101074000_79.8.505.9","doi-asserted-by":"crossref","first-page":"113371","DOI":"10.1016\/j.ejca.2023.113371","article-title":"Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression","volume":"195","author":"Atallah","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026071702101074000_79.8.505.10","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2010.200"},{"key":"2026071702101074000_79.8.505.11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx310"},{"key":"2026071702101074000_79.8.505.12","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.annonc.2025.04.006","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann Oncol"},{"key":"2026071702101074000_79.8.505.13","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"The Lancet"},{"key":"2026071702101074000_79.8.505.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.2747"},{"key":"2026071702101074000_79.8.505.15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34655"},{"key":"2026071702101074000_79.8.505.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100284"},{"key":"2026071702101074000_79.8.505.17","doi-asserted-by":"publisher","DOI":"10.2217\/fon.09.113"},{"key":"2026071702101074000_79.8.505.18","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2713"},{"key":"2026071702101074000_79.8.505.19","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1677\/erc.1.01054","article-title":"Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment","volume":"12 Suppl 1","author":"Gee","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"2026071702101074000_79.8.505.20","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.01044"},{"key":"2026071702101074000_79.8.505.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.5.1474."},{"key":"2026071702101074000_79.8.505.22","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.48.9.876"},{"key":"2026071702101074000_79.8.505.23","first-page":"716","article-title":"Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies","volume":"109","author":"McCarty","year":"1985","journal-title":"Arch Pathol Lab Med"},{"key":"2026071702101074000_79.8.505.24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/0377-4929.48906","article-title":"Quick score of hormone receptor status of breast carcinoma: correlation with the other clinicopathological prognostic parameters","volume":"52","author":"Mudduwa","year":"2009","journal-title":"Indian J Pathol Microbiol"},{"key":"2026071702101074000_79.8.505.25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds238"},{"key":"2026071702101074000_79.8.505.26","unstructured":"Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast: College of American Pathologists. Version: 1.6.0.0. 2025. Available: https:\/\/www.cap.org\/protocols-and-guidelines\/cancer-reporting-tools\/cancer-protocol-templates [accessed Mar 2026]"},{"key":"2026071702101074000_79.8.505.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.2574"},{"key":"2026071702101074000_79.8.505.28","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s12325-019-0896-0","article-title":"Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies","volume":"36","author":"Dixon","year":"2019","journal-title":"Adv Ther"},{"key":"2026071702101074000_79.8.505.29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.2831"},{"key":"2026071702101074000_79.8.505.30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.8411"},{"key":"2026071702101074000_79.8.505.31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10549-015-3651-5","article-title":"Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative\/progesterone receptor-positive invasive breast cancer phenotype","volume":"155","author":"Schroth","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2026071702101074000_79.8.505.32","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9238804","article-title":"The Prognosis and Predictive Value of Estrogen Negative\/Progesterone Positive (ER-\/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute","volume":"2022","author":"Gamrani","year":"2022","journal-title":"Breast J"},{"key":"2026071702101074000_79.8.505.33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03234"},{"key":"2026071702101074000_79.8.505.34","doi-asserted-by":"crossref","DOI":"10.1186\/s13000-023-01433-6","article-title":"Estrogen receptor-negative\/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy","volume":"19","author":"Dou","year":"2024","journal-title":"Diagn Pathol"},{"key":"2026071702101074000_79.8.505.35","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12282-018-0898-9","article-title":"Oestrogen receptor-negative\/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining","volume":"26","author":"Kuroda","year":"2019","journal-title":"Breast Cancer"},{"key":"2026071702101074000_79.8.505.36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.099"},{"key":"2026071702101074000_79.8.505.37","article-title":"Oestrogen Receptor Negative Progesterone Receptor Positive Phenotype in Breast Cancer is a Technical Artefact","volume":"228","author":"Rakha","year":"2012","journal-title":"J Path"},{"key":"2026071702101074000_79.8.505.38","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0902-SA"},{"key":"2026071702101074000_79.8.505.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00738-5"},{"key":"2026071702101074000_79.8.505.40","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05295-9"},{"key":"2026071702101074000_79.8.505.41","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/s41416-023-02426-4","article-title":"Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level","volume":"129","author":"Atallah","year":"2023","journal-title":"Br J Cancer"},{"key":"2026071702101074000_79.8.505.42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.breast.2023.07.008","article-title":"Differences between the efficacy of HER2(2+)\/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy","volume":"71","author":"Chen","year":"2023","journal-title":"Breast"},{"key":"2026071702101074000_79.8.505.43","doi-asserted-by":"crossref","first-page":"e877","DOI":"10.1093\/oncolo\/oyae047","article-title":"Comparison of the Response to Neoadjuvant Therapy Between Immunohistochemistry HER2 (3+) and HER2 (2+)\/ISH+ Early-Stage Breast Cancer: A Retrospective Multicenter Cohort Study","volume":"29","author":"Jiao","year":"2024","journal-title":"Oncologist"},{"key":"2026071702101074000_79.8.505.44","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1245\/s10434-024-16470-8","article-title":"Immunohistochemical Status Predicts Pathologic Complete Response to Neoadjuvant Therapy in HER2-Overexpressing Breast Cancers","volume":"32","author":"Winer","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"2026071702101074000_79.8.505.45","doi-asserted-by":"crossref","first-page":"775","DOI":"10.5858\/133.5.775","article-title":"Implementation of American Society of Clinical Oncology\/College of American Pathologists HER2 Guideline Recommendations in a Tertiary Care Facility Increases HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Concordance and Decreases the Number of Inconclusive Cases","volume":"133","author":"Middleton","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"2026071702101074000_79.8.505.46","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7819-7-83","article-title":"Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer","volume":"7","author":"Sui","year":"2009","journal-title":"World J Surg Oncol"},{"key":"2026071702101074000_79.8.505.47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10549-004-6275-8","article-title":"Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab","volume":"93","author":"Dybdal","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"2026071702101074000_79.8.505.48","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/cjp2.112","article-title":"Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients","volume":"4","author":"Dodson","year":"2018","journal-title":"The Journal of Pathology CR"},{"key":"2026071702101074000_79.8.505.49","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70336-9"},{"key":"2026071702101074000_79.8.505.50","doi-asserted-by":"crossref","first-page":"63571","DOI":"10.18632\/oncotarget.11541","article-title":"HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"key":"2026071702101074000_79.8.505.51","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605939"},{"key":"2026071702101074000_79.8.505.52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2154"},{"key":"2026071702101074000_79.8.505.53","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.breast.2017.06.022","article-title":"De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance","volume":"34 Suppl 1","author":"Veeraraghavan","year":"2017","journal-title":"Breast"},{"key":"2026071702101074000_79.8.505.54","doi-asserted-by":"publisher","DOI":"10.1126\/science.1073096"},{"key":"2026071702101074000_79.8.505.55","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000525092","article-title":"Assessment of Predictive Biomarkers in Breast Cancer: Challenges and Updates","volume":"89","author":"Rakha","year":"2022","journal-title":"Pathobiology"},{"key":"2026071702101074000_79.8.505.56","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1470-2045(17)30021-9","article-title":"HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial","volume":"18","author":"Llombart-Cussac","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026071702101074000_79.8.505.57","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz042"},{"key":"2026071702101074000_79.8.505.58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.9984"},{"key":"2026071702101074000_79.8.505.59","doi-asserted-by":"publisher","DOI":"10.1136\/jcp-2022-208632"},{"key":"2026071702101074000_79.8.505.60","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01351-8"},{"key":"2026071702101074000_79.8.505.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2017.03.016"},{"key":"2026071702101074000_79.8.505.62","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225694","article-title":"Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis","volume":"13","author":"Cserni","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026071702101074000_79.8.505.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.03.001"},{"key":"2026071702101074000_79.8.505.64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1943"},{"key":"2026071702101074000_79.8.505.65","first-page":"40","article-title":"Triple-negative\/basal-like breast cancer: review","volume":"41","author":"Rakha","year":"2009","journal-title":"Pathology (Phila)"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp-2026-210723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T09:11:06Z","timestamp":1784279466000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp-2026-210723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":65,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,7,17]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/jcp-2026-210723"],"URL":"https:\/\/doi.org\/10.1136\/jcp-2026-210723","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]}}}